Westergaard J G, Lange A P, Pedersen G T, Secher N J
Acta Obstet Gynecol Scand. 1983;62(2):103-10. doi: 10.3109/00016348309155772.
A randomized comparative study of 387 consecutive patients admitted for induction of labor was carried out using two orally administered oxytocics (prostaglandin E2 tablets (Prostin) or Demoxytocin resoriblets for buccal administration (Sandopart)), the results of which are reported here. One-hundred and twenty-three cases were suitable for primary amniotomy; of these 48 were given PGE2 tablets and 75 received demoxytocin resoriblets. In a further 264 cases, primary amniotomy was inadvisable and of these, 133 patients were allotted to the PGE2 treatment group and 131 to treatment with demoxytocin. A significantly higher success rate was observed (p less than 0.05) in the PGE2 group in cases where primary amniotomy had been carried out, as compared with the demoxytocin group. Parturition was successfully induced in 82.0% of the patients given PGE2 tablets, as against only 63.4% of those receiving demoxytocin following 2 days of stimulation without primary amniotomy. This difference is statistically significant at the 0.001 level, and presumably due to the highly significant difference (p less than 0.0001) between patients with a Bishop score of 5 or less, where induction was successful in 75.4% given PGE2 tablets, in contrast to a success rate of only 36.7% in patients receiving demoxytocin resoriblets. No difference was observed in the success rate between the two treatment groups when the Bishop score was 6 or more. No difference was recorded in the incidence of fetal distress, instrumental delivery or low Apgar score between the two treatment groups. However, a higher incidence of vomiting and diarrhea were observed in patients treated with PGE2 tablets (11%) as compared with those receiving demoxytocin (1.5%). There was no difference with regard to the induction-delivery time, nor to the different stages of labor between otherwise comparable treatment groups when the induction was successful. It is concluded in respect of induction of labor using orally administered oxytocics that PGE2 (tablets) are preferable to demoxytocin (resoriblets) as it is the more effective of the two.
对387例连续入院引产的患者进行了一项随机对照研究，使用两种口服催产剂（前列腺素E2片（普罗斯汀）或用于口腔给药的地莫催产素含片（桑多帕特）），本文报告了研究结果。123例适合进行原发性羊膜穿刺术；其中48例给予前列腺素E2片，75例接受地莫催产素含片。在另外264例中，原发性羊膜穿刺术不可行，其中133例患者被分配到前列腺素E2治疗组，131例接受地莫催产素治疗。与地莫催产素组相比，在进行原发性羊膜穿刺术的病例中，前列腺素E2组观察到显著更高的成功率（p<0.05）。给予前列腺素E2片的患者中有82.0%成功引产，而在未进行原发性羊膜穿刺术的2天刺激后，接受地莫催产素的患者中只有63.4%成功引产。这种差异在0.001水平上具有统计学意义，可能是由于Bishop评分≤5分的患者之间存在高度显著差异（p<0.0001），给予前列腺素E2片的患者引产成功率为75.4%，而接受地莫催产素含片的患者成功率仅为36.7%。当Bishop评分≥6分时，两个治疗组的成功率没有差异。两个治疗组在胎儿窘迫、器械助产或低Apgar评分的发生率方面没有差异。然而，与接受地莫催产素的患者（1.5%）相比，给予前列腺素E2片治疗的患者呕吐和腹泻的发生率更高（11%）。在引产成功时，在诱导分娩时间方面以及在其他方面可比的治疗组之间的不同产程方面没有差异。关于使用口服催产剂引产得出的结论是，前列腺素E2（片剂）比地莫催产素（含片）更可取，因为它在两者中更有效。
